¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"y"¿¡ ´ëÇÑ Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú :
5
ÆäÀÌÁö:
19
ÄÚµå
¿µ¹®
ÇѱÛ
Y71
Cardiovascular devices associated with adverse incidents
À¯ÇØ»ç°Ç°ú °ü·ÃµÈ ½ÉÀåÇ÷°ü ÀåÄ¡
Y40.1
Cefalosporins and other ¥â-lactam antibiotics
¼¼ÆÈ·Î½ºÆ÷¸° ¹× ±âŸ º£Å¸¶ôŽ Ç×»ýÁ¦
Y50.9
Central nervous system stimulant, unspecified
»ó¼¼ºÒ¸íÀÇ ÁßÃ߽Űæ°èÅë ÈïºÐÁ¦
Y50
Central nervous system stimulants, NEC
´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ÁßÃ߽Űæ°èÅë ÈïºÐÁ¦
Y51.8
Centrally acting and adrenergic-neuron-blocking agents, NEC
´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ÁßÃß¼º ÀÛ¿ë ¹× ¾Æµå·¹³ÊÁ÷ ´º·Ð Â÷´ÜÁ¦
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
19
ÄÚµå
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½